ArticleJournal of nanobiotechnology2025
Coptis chinensis-derived extracellular vesicle-like nanoparticles delivered miRNA-5106 suppresses NETs by restoring zinc homeostasis to alleviate colitis.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neutrophil extracellular traps as a potential therapeutic target in inflammatory bowel disease: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Advances in Chinese herbal medicine for diabetic wound treatment: from tradition to innovation.Chinese medicine · 2026Review
- From waste to wellness: pomelo peel derived exosome-like nanoparticles reshape gut microbiota and enhance beneficial metabolites.Food chemistry: X · 2026Article
- Reshaping the immune landscape: next-generation microglia-targeted therapies for Alzheimer's disease.Biological research · 2026Review
- Disrupting intestinal cell pyroptosis-NETs crosstalk reverse mucosal damage and restore Treg/Th17 equilibrium in ulcerative colitis via a calcium pectate microsphere composite hydrogel.Journal of nanobiotechnology · 2026Article
- Advances in Nano-Drug Delivery Systems for Chronic Autoimmune Diseases: A Focus on Diabetes Mellitus, Inflammatory Bowel Disease, and Rheumatoid Arthritis.Molecules (Basel, Switzerland) · 2026Review
- Recent progress of plant-derived extracellular vesicle-like nanoparticles integrated with biomaterials for skin repair.Journal of nanobiotechnology · 2026Review
- Engineered bone-targetingMaterials today. Bio · 2026Article
- All-in-one: a CGRP-encapsulated Rh-GelMA supramolecular dual-network hydrogel orchestrating immune-vascular coupling for diabetic wound healing.Journal of nanobiotechnology · 2026Article
- Plant-Derived Nanovesicles: A Comprehensive Review from Isolation to Clinical Translation-Unlocking Natural Nanocarriers for Biomedical Applications.Biomolecules · 2026Review
- Biogenesis, preparation, characterization, therapeutic mechanisms and safety evaluation of plant-derived exosome-like nanovesicles in the treatment of ulcerative colitis.Journal of nanobiotechnology · 2026Review
- Plant-Derived Vesicle-like Nanoparticles for Cancer Therapy: From Drug Delivery to Combined Immunotherapy.Antioxidants (Basel, Switzerland) · 2026Review
- Microneedle-mediated delivery of Coptis chinensis-derived nanovesicles orchestrating antibacterial and macrophage reprogramming for comprehensive wound healing.Journal of nanobiotechnology · 2026Article
- Artemisiae Argyi exosome-like nanovesicles alleviate ALF by reducing oxidative stress and inhibiting inflammation through the TLR4/NLRP3/Nrf2 axis.Chinese medicine · 2026Article
- Oral plant-derived exosome-like nanovesicles: a new therapeutic perspective for intestinal diseases.Frontiers in pharmacology · 2026Review
- Extracellular Vesicles for Therapeutic Applications: A Translational Framework Integrating Sources, Administration Routes, Indications, Quality Control, and Regulatory Systems.International journal of nanomedicine · 2026Review
- Plant-derived vesicle-like nanoparticles for immunomodulation: Mechanisms and applications.Bioactive materials · 2026Review
- Plant-Derived Exosome-Like Nanoparticles: Mechanisms of Cross-Kingdom Regulation and Perspectives as Natural Drug Carriers for Disease Treatment.International journal of nanomedicine · 2026Review
- miRNAs-neutrophil axis: novel insights into acute lung injury and chronic inflammatory lung diseases.Frontiers in immunology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundInflammatory bowel disease (IBD) is a chronic disorder marked by persistent inflammation and damage to the intestinal mucosa. Despite significant advances in treatment, there remains an unmet need for more effective and safer therapeutic strategies.
resultsIn this study, we isolated and characterized extracellular vesicle-like nanoparticles (ELNs) derived from Coptis chinensis (Cc-ELNs) and evaluated their therapeutic potential in IBD. Intraperitoneal administration of Cc-ELNs in dextran sulfate sodium (DSS)-induced colitis mice demonstrated selective targeting of inflamed intestinal regions. Cc-ELNs significantly alleviated colitis by reducing neutrophil recruitment and inhibiting the formation of neutrophil extracellular traps (NETs). Furthermore, by suppressing NET formation, Cc-ELNs mitigated pyroptosis in intestinal epithelial cells (IECs) and promoted the proliferation of both IECs and intestinal stem cells (ISCs). Mechanistically, Cc-ELNs delivered miR-5106, which downregulated Slc39a2 expression, thereby restoring zinc homeostasis in neutrophils and reducing NET formation.
conclusionsThese findings establish Cc-ELNs as a novel, natural, and effective therapeutic candidate for IBD, highlighting the potential of plant-derived nanoparticle-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.